REGN:NSD-Regeneron Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 506.48

Change

+2.06 (+0.41)%

Market Cap

USD 54.04B

Volume

0.61M

Average Target Price

USD 620.40 (+22.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing REGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+2.55 (+1.39%)

USD0.50B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+2.26%)

USD0.34B
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.30 %

+0.28 (+0.60%)

USD3.51B
FTGU:XETRA First Trust US Large Cap .. 0.00 % 0.00 %

+0.52 (+0.96%)

USD0.09B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.12%)

USD0.35B
XDEB:F Xtrackers MSCI World Mini.. 0.00 % 0.25 %

+0.19 (+0.61%)

USD0.53B
SXR0:F iShares Edge MSCI World M.. 0.00 % 0.35 %

+0.03 (+0.38%)

N/A
IQQ0:F iShares Edge MSCI World M.. 0.00 % 0.30 %

+0.24 (+0.50%)

USD3.51B
XDEB:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.25 %

+15.50 (+0.57%)

USD0.76B
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

+50.00 (+0.93%)

USD5.81B
VMOM:LSE Vanguard Global Momentum .. 0.00 % 0.00 %

N/A

USD0.07B
MINV:LSE iShares Edge MSCI World M.. 0.00 % 0.30 %

+20.50 (+0.51%)

USD3.51B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.16 (+2.28%)

USD0.03B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.15 (+2.27%)

USD0.34B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+3.23 (+3.80%)

USD0.20B
HERS-B:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.24 (+2.73%)

USD0.29B
BUL Pacer US Cash Cows Growth.. 0.00 % 0.60 %

+0.48 (+1.31%)

USD3.42M
DWSH AdvisorShares Dorsey Wrig.. 0.00 % 3.67 %

-0.05 (-0.55%)

USD0.03B
HERS:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

USD3.37M
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.35 %

N/A

USD0.26B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

-2.53 (-10.14%)

USD0.07B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

+2.99 (+1.97%)

USD10.74B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.86 (-3.91%)

USD0.01B
XDEB:XETRA Xtrackers (IE) Plc - Xtra.. 0.00 % 0.25 %

+0.20 (+0.62%)

USD0.76B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.84% 57% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.84% 57% F 45% F
Trailing 12 Months  
Capital Gain -9.25% 31% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.25% 31% F 10% F
Trailing 5 Years  
Capital Gain 25.25% 62% D- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.25% 62% D- 37% F
Average Annual (5 Year Horizon)  
Capital Gain 14.85% 52% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.85% 52% F 64% D
Risk Return Profile  
Volatility (Standard Deviation) 38.19% 77% C+ 45% F
Risk Adjusted Return 38.87% 63% D 61% D-
Market Capitalization 54.04B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.53 37% F 58% F
Price/Book Ratio 4.86 48% F 35% F
Price / Cash Flow Ratio 20.64 5% F 22% F
EV/EBITDA 12.83 32% F 64% D
Management Effectiveness  
Return on Equity 31.77% 98% A+ 95% A
Return on Invested Capital 27.22% 93% A 94% A
Return on Assets 12.88% 97% A+ 97% A+
Debt to Equity Ratio 17.94% 45% F 63% D
Technical Ratios  
Short Ratio 2.36 59% F 47% F
Short Percent 2.85% 79% C+ 55% F
Beta 0.19 93% A 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.